乳腺导管原位癌:发病率、治疗和结局的系统评价。
Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes.
机构信息
Division of Health Policy and Management, University of Minnesota School of Public Health, A365 Mayo (MMC 729), Minneapolis, MN 55455, USA.
出版信息
J Natl Cancer Inst. 2010 Feb 3;102(3):170-8. doi: 10.1093/jnci/djp482. Epub 2010 Jan 13.
BACKGROUND
The National Institutes of Health Office of Medical Applications of Research commissioned a structured literature review on the incidence, treatment, and outcomes of ductal carcinoma in situ (DCIS) as a background article for the State of the Science Conference on Diagnosis and Management of DCIS.
METHODS
Published studies were identified and abstracted from MEDLINE and other sources. We include articles published between 1965 and January 31, 2009; 374 publications were identified that addressed DCIS incidence, staging, treatment, and outcomes in adult women.
RESULTS
In the United States, DCIS incidence rose from 1.87 per 100 000 in 1973-1975 to 32.5 in 2004. Incidence increased in all ages but more so in women older than 50 years. Increased use of mammography explains some but not all of the increased incidence. Risk factors for incident DCIS include older age and family history. Although tamoxifen treatment prevented both invasive breast cancer and DCIS, raloxifene treatment decreased incidence of invasive breast cancer but not DCIS. Among patients with DCIS, magnetic resonance imaging was more sensitive than mammography for detecting multicentric disease and estimating tumor size. Because about 15% of patients with DCIS identified on core needle biopsy are diagnosed with invasive breast cancer after excision or mastectomy, the accuracy of sentinel lymph node biopsy after excision is relevant to surgical management of DCIS. Most studies demonstrated that sentinel lymph node biopsy is feasible after breast-conserving surgery (BCS). Younger age, positive surgical margins, tumor size and grade, and comedo necrosis were consistently related to DCIS recurrence. DCIS outcomes after either mastectomy or BCS plus radiation therapy were superior to BCS alone. Tamoxifen treatment after DCIS diagnosis reduced risk of recurrent disease.
CONCLUSIONS
Scientific questions deserving further investigation include the relationship between mammography use and DCIS incidence and whether imaging technologies and treatment guidelines can be modified to focus on lesions that are most likely to become clinically problematic.
背景
美国国立卫生研究院医学应用研究办公室委托进行了一项关于导管原位癌(DCIS)发病率、治疗和结局的结构化文献综述,作为 DCIS 诊断和管理科学会议的背景文章。
方法
从 MEDLINE 和其他来源中确定并提取已发表的研究。我们包括了发表于 1965 年至 2009 年 1 月 31 日的文章,共 374 篇文章涉及成年女性 DCIS 的发病率、分期、治疗和结局。
结果
在美国,DCIS 的发病率从 1973-1975 年的每 10 万人 1.87 例上升到 2004 年的 32.5 例。所有年龄段的发病率都有所上升,但 50 岁以上的女性上升更为明显。乳房 X 线照相术的广泛应用解释了部分但不是全部发病率的增加。DCIS 的发病风险因素包括年龄较大和家族史。虽然他莫昔芬治疗可预防浸润性乳腺癌和 DCIS,但雷洛昔芬治疗可降低浸润性乳腺癌的发病率,但不能降低 DCIS 的发病率。在 DCIS 患者中,磁共振成像比乳房 X 线照相术更能敏感地检测多中心疾病并估计肿瘤大小。由于在核心针活检中诊断为 DCIS 的患者中有 15%左右在切除或乳房切除术后被诊断为浸润性乳腺癌,因此切除后前哨淋巴结活检的准确性与 DCIS 的手术管理相关。大多数研究表明,保乳手术后(BCS)可行前哨淋巴结活检。年轻、阳性切缘、肿瘤大小和分级以及粉刺样坏死与 DCIS 复发始终相关。与 BCS 相比,BCS 加放射治疗后行乳房切除术或 DCIS 的结局更优。DCIS 诊断后使用他莫昔芬治疗可降低疾病复发的风险。
结论
有待进一步研究的科学问题包括乳房 X 线照相术使用与 DCIS 发病率之间的关系,以及是否可以修改成像技术和治疗指南,以聚焦最有可能出现临床问题的病变。